In this issue of *Critical Care*, Camporota and colleagues [1] report interesting observations on the relationship between the initial gas exchange response to high-frequency oscillatory ventilation (HFOV) and clinical outcomes. HFOV seems ideally suited to protecting the lung during mechanical ventilation in patients with acute respiratory distress syndrome (ARDS). By delivering very small tidal volumes and allowing higher mean airway pressures, HFOV can potentially minimize both volutrauma and atelectrauma [2]. However, the recently published OSCILLATE (OSCillation in ARDS Treated Early) [3] and OSCAR (High-Frequency OSCillation in ARDS) [4] trials – both of which postdate the article by Camporota and colleagues – found that HFOV failed to reduce mortality. In particular, OSCILLATE raised questions of potential harm from HFOV. In the face of these disappointing results, trialists and clinicians alike are left wondering how to reconcile theory to practice. A number of potential mechanisms for harm have been postulated, including (a) the deleterious effects of increased sedation, (b) hemodynamic embarrassment due to reduced right ventricular preload or increased right ventricular afterload, or (c) an increase in mechanical alveolar stress and strain within the baby lung [5]. Some combination of these mechanisms is likely to contribute to patient outcome during HFOV.

A critical factor influencing the importance of these various mechanisms may be the response of the individual patient to the application of high mean airway pressures. Imaging studies have demonstrated profound heterogeneity in the extent of alveolar recruitment in response to increases in airway pressure [6,7]. In patients with ‘recruitable lung,’ higher airway pressures increase the size of the functional ‘baby lung,’ reduce alveolar stress and strain, and may even reduce right ventricular afterload without significantly compromising right ventricular filling [8]. In patients lacking ‘recruitable lung,’ higher mean airway pressures achieve the opposite: worsened alveolar stress and strain and increased right ventricular afterload. Consequently, the potential for benefit or harm may depend critically on the degree of lung recruitment in response to increasing mean airway pressure.

Enter the interesting observations of Camporota and colleagues [1], who found that in patients with moderate or severe ARDS who were placed on HFOV by their attending physicians, the change in arterial partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio 6 hours after HFOV initiation was associated with 30-day survival. Improvements in oxygenation were also associated with reductions in arterial partial pressure of carbon dioxide (PaCO2), particularly in patients with more severe respiratory failure, contradicting the widely held belief that HFOV inevitably worsens respiratory acidosis.

The oxygenation response to increased positive end-expiratory pressure (PEEP) is the product of a complex interplay between alveolar recruitment and cardiac output. Classic physiological studies by Dantzker and colleagues [9] and Lynch and colleagues [10] demonstrated that increased PEEP reduces intrapulmonary shunt both by re-opening collapsed lung units and by reducing cardiac output. In the latter case, non-ventilated lung units are preferentially affected by reduced blood
flow, possibly because of the effects of hypoxic pulmonary vasoconstriction [11]. In the present study, Camporota and colleagues reported that cardiac output was unchanged; thus, the short-term oxygenation response likely signifies lung recruitment.

The authors speculate that the gas exchange response may be a useful predictor of the utility of HFOV in the difficult-to-oxygenate patient and further propose that failure to demonstrate improved oxygenation after a 6-hour trial of HFOV should prompt a consideration of alternative rescue modalities such as extracorporeal life support. It is difficult, however, to do anything more than speculate on the basis of these data. First, it is difficult to be certain whether the association between early improvements in oxygenation and reduced mortality arises from the effects of HFOV-induced lung recruitment or simply represents the natural history of survivors (whose oxygenation will tend to improve with time) in contrast to non-survivors (whose oxygenation will tend to worsen with time). Second, even if the improvements in oxygenation were directly related to lung recruitment, it is impossible to discern whether oxygenation ‘responders’ have lower mortality than ‘non-responders’ because ‘responders’ have a less fatal form of ARDS or because they accrue greater benefit from HFOV. Finally, from these data in which all patients received HFOV, it is impossible to know whether increases in mean airway pressure on conventional ventilation would have been equally effective.

Such issues can be resolved only by a carefully designed randomized trial of an open-lung ventilation strategy that stratifies patients by oxygenation response prior to random assignment. In the meantime, in light of the available evidence, HFOV should usually be reserved for patients with refractory hypoxemia. When applying HFOV, clinicians should consider monitoring lung recruitment (by oxygenation response or other means available) and right ventricular function (by echocardiography or other hemodynamic monitoring) to ensure that this unique mode of ventilation is achieving appropriate physiological goals in the individual patient.